ニーズの概略

PfizerがInternal Medicine(Metabolic Diseases)に関する技術を募集しています。

Metabolic Diseases, specifically Type 2 diabetes (T2D), NAFLD/NASH and obesity, are major health problems that have reached epidemic proportions worldwide. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies.

We are interested in establishing alliances to develop and access:

-Metabolic therapies for non-alcoholic, fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)

-Dyslipidemia Obesity and Eating Disorders

-Diabetes and related co-morbidities Specific areas of interest include:

-Decreasing hepatic lipid content and inflammation and the development of liver fibrosis in patients with NASH/NAFLD

-Identifying and qualifying novel biomarkers non-invasive biomarkers for NAS

-Improving cardiac performance via metabolic reprogramming of more efficient energetic

-Novel therapies that reduce hyperinsulinemia and hyperglycemia. Addressing obesity and eating disorders to induce and sustain weight loss

-Brain signals that regulate energy homeostasis and metabolis

-Centrally-acting anorectics

以上の技術ニーズは、Pfizerが公式ウェブサイトにて開示したものを取得したものであり、弊社は当該ニーズ提供者の代理人ではありません。